-
1Academic Journal
Authors: A. R. Bosieva, M. V. Ermoshchenkova, N. N. Volchenko, A. D. Zikiryahodjaev, А. Р. Босиева, М. В. Ермощенкова, Н. Н. Волченко, А. Д. Зикиряходжаев
Source: Siberian journal of oncology; Том 20, № 4 (2021); 116-121 ; Сибирский онкологический журнал; Том 20, № 4 (2021); 116-121 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-4
Subject Terms: края резекции, neoadjuvant chemotherapy, breast-conserving surgery, resection margins, неоадъювантная лекарственная терапия, органосохраняющие операции
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1873/891; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. 250 с.; Munhoz A.M., Montag E., Gemperli R. Oncoplastic breast surgery: indications, techniques and perspectives. Gland Surg. 2013 Aug; 2(3): 143–57. doi:10.3978/j.issn.2227-684X.2013.08.02.; Исмагилов А.Х., Ванесян А.С., Хамитов А.Р., Камалетдинов И.Ф. Онкопластическая хирургия молочной железы: основы, классификация, алгоритм выполнения. Опухоли женской репродуктивной системы. 2014; 4: 37–42.; Veronesi U., Banfi A., Salvadori B., Luini A., Saccozzi R., Zucali R., Marubini E., Del Vecchio M., Boracchi P., Marchini S. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer. 1990; 26(6): 668–70. doi:10.1016/0277-5379(90)90113-8.; Пак Д.Д., Рассказова Е.А. Органосохраняющие операции при раке молочной железы. Опухоли женской репродуктивной системы. 2011; 2: 22–27.; Зикиряходжаев А.Д., Чиссов В.И., Ермощенкова М.В., Сухотько А.С., Тукмаков А.Ю. Методологические аспекты и результаты онкопластических резекций молочной железы. Онкология. Журнал им. П.А. Герцена. 2016; 2(5): 4–11.; Franceschini G., Martin Sanchez A., Di Leone A., Magno S., Moschella F., Accetta C., Masetti R. New trends in breast cancer surgery: a therapeutic approach increasingly efficacy and respectful of the patient. G Chir. 2015 Jul-Aug; 36(4): 145–52. doi:10.11138/gchir/2015.36.4.145.; Ермощенкова М.В., Зикиряходжаев А.Д., Широких И.М., Тукмаков А.В., Масри А.А., Запиров М.М. Хирургическая реабилитация больных раком молочной железы на различных этапах комбинированного и комплексного лечения. Онкология. Журнал им. П.А. Герцена. 2019; 3(8): 161–169.; Fitoussi A.D., Berry M.G., Famà F., Falcou M.C., Curnier A., Couturaud B., Reyal F., Salmon R.J. Oncoplastic breast surgery for cancer: analysis of 540 consecutive cases [outcomes article]. Plast Reconstr Surg. 2010 Feb; 125(2): 454–462. doi:10.1097/PRS.0b013e3181c82d3e.; Asgeirsson K.S., Rasheed T., McCulley S.J., Macmillan R.D. Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2005 Oct; 31(8): 817–23. doi:10.1016/j.ejso.2005.05.010.; Chen A.M., Meric-Bernstam F., Hunt K.K., Thames H.D., Oswald M.J., Outlaw E.D., Buchholz T.A. Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson cancer center experience. J Clin Oncol. 2004; 12(22): 2303–12.; Boughey J.C., Peintinger F., Meric-Bernstam F., Perry A.C., Hunt K.K., Babiera G.V., Singletary S.E., Bedrosian I., Lucci A., Buzdar A.U., Pusztai L., Kuerer H.M. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3): 464–70. doi:10.1097/01.sla.0000234897.38950.5c.; Mazouni C., Naveau A., Kane A., Dunant A., Garbay J.R., Leymarie N., Sarfati B., Delaloge S., Rimareix F. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. Breast. 2013 Dec; 22(6): 1189–93. doi:10.1016/j.breast.2013.07.055.; Silverstein M.J., Savalia N., Khan S., Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. Breast J. 2015 JanFeb; 21(1): 52–9. doi:10.1111/tbj.12356.; Koppiker C.B., Noor A.U., Dixit S., Busheri L., Sharan G., Dhar U., Allampati H.K., Nare S. Extreme Oncoplastic Surgery for Multifocal/ Multicentric and Locally Advanced Breast Cancer. Int J Breast Cancer. 2019 Feb 20; 2019: 4262589. doi:10.1155/2019/4262589.; Pearce B.C.S., Fiddes R.N., Paramanathan N., Chand N., Laws S.A.M., Rainsbury R.M. Extreme oncoplastic conservation is a safe new alternative to mastectomy. Eur J Surg Oncol. 2020; 46(1): 71–76. doi:10.1016/j.ejso.2019.09.004.; Curigliano G., Burstein H.J., Winer E.P., Gnant M., Dubsky P., Loibl S., Colleoni M., Regan M.M., Piccart-Gebhart M., Senn H.J., Thürlimann B.; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F., Baselga J., Bergh J., Bonnefoi H., Brucker S.Y., Cardoso F., Carey L., Ciruelos E., Cuzick J., Denkert C., Di Leo A., Ejlertsen B., Francis P., Galimberti V., Garber J., Gulluoglu B., Goodwin P., Harbeck N., Hayes D.F., Huang C.S., Huober J., Hussein K., Jassem J., Jiang Z., Karlsson P., Morrow M., Orecchia R., Osborne K.C., Pagani O., Partridge A.H., Pritchard K., Ro J., Rutgers E.J.T., Sedlmayer F., Semiglazov V., Shao Z., Smith I., Toi M., Tutt A., Viale G., Watanabe T., Whelan T.J., Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8): 1700–12. doi:10.1093/annonc/mdx308.; Choi J., Laws A., Hu J., Barry W., Golshan M., King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol. 2018 Nov; 25(12): 3541–3547. doi:10.1245/s10434-018-6702-4.; Rouzier R., Extra J.M., Carton M., Falcou M.C., Vincent-Salomon A., Fourquet A., Pouillart P., Bourstyn E. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001 Sep 15; 19(18): 3828–35. doi:10.1200/JCO.2001.19.18.3828.; Valachis A., Mamounas E.P., Mittendorf E.A., Hayashi N., Ishitobi M., Natoli C., Fitzal F., Rubio I.T., Tiezzi D.G., Shin H.C., Anderson S.J., Hunt K.K., Matsuda N., Ohsumi S., Totomi A., Nilsson C. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018; 124(14): 2923–30. doi:10.1002/cncr.31518.; Mamounas E.P., Anderson S.J., Dignam J.J., Bear H.D., Julian T.B., Geyer C.E.Jr., Taghian A., Wickerham D.L., Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10; 30(32): 3960–6. doi:10.1200/JCO.2011.40.8369.; Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3): 188–94. doi:10.1093/jnci/dji021.; Mieog J.S., van der Hage J.A., van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007; 94(10): 1189–200. doi:10.1002/bjs.5894.; Volders J.H., Haloua M.H., Krekel N.M., Negenborn V.L., Barbé E., Sietses C., Jóźwiak K., Meijer S., van den Tol M.P.; the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA). Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol. 2016 Jul; 42(7): 986–93. doi:10.1016/j.ejso.2016.02.252.; https://www.siboncoj.ru/jour/article/view/1873
-
2Academic Journal
Authors: A. R. Bosieva, M. V. Ermoshchenkova, A. D. Zikiryakhodzhayev, N. N. Volchenko, А. Р. Босиева, М. В. Ермощенкова, А. Д. Зикиряходжаев, Н. Н. Волченко
Source: Siberian journal of oncology; Том 20, № 2 (2021); 118-126 ; Сибирский онкологический журнал; Том 20, № 2 (2021); 118-126 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-2
Subject Terms: косметические результаты, neoadjuvant chemotherapy, breast-conserving surgery, margin status, volume of tissue removed, cosmetic outcomes, неоадъювантная лекарственная терапия, органосохраняющие операции, края резекции, ререзекция, объем удаляемых тканей, рецидив
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1764/855; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. с. 250.; Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007 Apr 18; 2007(2): CD005002. doi:10.1002/14651858.CD005002.pub2.; Mittendorf E.A., Buchholz T.A., Tucker S.L., Meric-Bernstam F., Kuerer H.M., Gonzalez-Angulo A.M., Bedrosian I., Babiera G.V., Hoffman K., Yi M., Ross M.I., Hortobagyi G.N., Hunt K.K. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013; 257(2): 173–9. doi:10.1097/SLA.0b013e3182805c4a.; Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 2; 97(3): 188–94. doi:10.1093/jnci/dji021.; Curran D., van Dongen J.P., Aaronson N.K., Kiebert G., Fentiman I.S., Mignolet F., Bartelink H. Quality of life of early- stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer. 1998 Feb; 34(3): 307–14. doi:10.1016/s0959-8049(97)00312-2.; Kim M.K., Kim T., Moon H.G., Jin U.S., Kim K., Kim J., Lee J.W., Kim J., Lee E., Yoo T.K., Noh D.Y., Minn K.W., Han W. Effect of cosmetic outcome on quality of life after breast cancer surgery. Eur J Surg Oncol. 2015 Mar; 41(3): 426–32. doi:10.1016/j.ejso.2014.12.002.; Arndt V., Stegmaier C., Ziegler H., Brenner H. Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol. 2008 Dec; 134(12): 1311–8. doi:10.1007/s00432-008-0418-y.; Jagsi R., Li Y., Morrow M., Janz N., Alderman A., Graff J., Hamilton A., Katz S., Hawley S. Patient-reported Quality of Life and Satisfaction With Cosmetic Outcomes After Breast Conservation and Mastectomy With and Without Reconstruction: Results of a Survey of Breast Cancer Survivors. Ann Surg. 2015 Jun; 261(6): 1198–206. doi:10.1097/SLA.0000000000000908.; Markopoulos C., Tsaroucha A.K., Kouskos E., Mantas D., Antonopoulou Z., Karvelis S. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. J Int Med Res. 2009 Jan-Feb; 37(1): 182–8. doi:10.1177/147323000903700122.; Vrieling C., Collette L., Fourquet A., Hoogenraad W.J., Horiot J.H., Jager J.J., Pierart M., Poortmans P.M., Struikmans H., Maat B., Van Limbergen E., Bartelink H. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000; 55(3): 219–32. doi:10.1016/s0167-8140(00)00210-3.; Immink J.M., Putter H., Bartelink H., Cardoso J.S., Cardoso M.J., van der Hulst-Vijgen M.H.V., Noordijk E.M., Poortmans P.M., Rodenhuis C.C., Struikmans H. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC ‘boost versus no boost’ trial. Ann Oncol. 2012 Oct; 23(10): 2591–98. doi:10.1093/annonc/mds066.; Cochrane R.A., Valasiadou P., Wilson A.R., Al-Ghazal S.K., Macmillan R.D. Cosmesis and satisfaction after breast- conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003 Dec; 90(12): 1505–9. doi:10.1002/bjs.4344.; Taylor M.E., Perez C.A., Halverson K.J., Kuske R.R., Philpott G.W., Garcia D.M., Mortimer J.E., Myerson R.J., Radford D., Rush C. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4): 753–64. doi:10.1016/0360-3016(94)00480-3.; Hennigs A., Hartmann B., Rauch G., Golatta M., Tabatabai P., Domschke C., Schott S., Schütz F., Sohn C., Heil J. Long-term objective esthetic outcome after breast-conserving therapy. Breast Cancer Res Treat. 2015 Sep; 153(2): 345–51. doi:10.1007/s10549-015-3540-y.; Haloua M.H., Volders J.H., Krekel N.M., Lopes Cardozo A.M., de Roos W.K., de Widt-Levert L.M., van der Veen H., Rijna H., Bergers E., Jóźwiak K., Meijer S., van den Tol P. Intraoperative Ultrasound Guidance in Breast-Conserving Surgery Improves Cosmetic Outcomes and Patient Satisfaction: Results of a Multicenter Randomized Controlled Trial (COBALT). Ann Surg Oncol. 2016; 23(1): 30–7. doi:10.1245/s10434-015-4906-4.; Parvez E., Cornacchi S.D., Hodgson N., Thoma A., Kong I., Foster G., Cheng J., Goldsmith C.H., Dao D., Lovrics P.J. A cosmesis outcome substudy in a prospective, randomized trial comparing radioguided seed localization with standard wire localization for nonpalpable, invasive, and in situ breast carcinomas. Am J Surg. 2014 Nov; 208(5): 711–8. doi:10.1016/j.amjsurg.2014.05.030.; King T.A., Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015 Jun; 12(6): 335–43. doi:10.1038/nrclinonc.2015.63.; Bossuyt V., Provenzano E., Symmans W.F., Boughey J.C., Coles C., Curigliano G., Dixon J.M., Esserman L.J., Fastner G., Kuehn T., Peintinger F., von Minckwitz G., White J., Yang W., Badve S., Denkert C., MacGrogan G., Penault-Llorca F., Viale G., Cameron D.; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul; 26(7): 1280–91. doi:10.1093/annonc/mdv161.; Mukhtar R.A., Yau C., Rosen M., Tandon V.J.; I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N., Esserman L.J. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12): 3823–30. doi:10.1245/s10434-013-3038-y.; Howick J., Chalmers I., Glasziou P. The Oxford 2011 levels of evidence. Oxford centre evidence-based medicine. 2011. 11.; Boughey J.C., Peintinger F., Meric-Bernstam F., Perry A.C., Hunt K.K., Babiera G.V., Singletary S.E., Bedrosian I., Lucci A., Buzdar A.U., Pusztai L., Kuerer H.M. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3): 464–70. doi:10.1097/01.sla.0000234897.38950.5c.; Waljee J.F., Hu E.S., Newman L.A., Alderman A.K. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008 May; 15(5): 1297–303. doi:10.1245/s10434-007-9777-x.; Komenaka I.K., Hibbard M.L., Hsu C.H., Low B.G., Salganick J.A., Bouton M.E., Jha C. Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting. Oncologist. 2011; 16(6): 752–9. doi:10.1634/theoncologist.2010-0268.; Karanlik H., Ozgur I., Cabioglu N., Sen F., Erturk K., Kilic B., Onder S., Deniz M., Yavuz E., Aydiner A. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome. Eur J Surg Oncol. 2015 Sep; 41(9): 1226–33. doi:10.1016/j.ejso.2015.06.003.; Christy C.J., Thorsteinsson D., Grube B.J., Black D., Abu-Khalaf M., Chung G.G., DiGiovanna M.P., Miller K., Higgins S.A., Weidhaas J., Harris L., Tavassoli F.A., Lannin D.R. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 16(3): 697–702. doi:10.1245/s10434-008-0268-5.; Kryh C.G., Pietersen C.A., Rahr H.B., Christensen R.D., Wamberg P., Lautrup M.D. Re-resection rates and risk characteristics following breast conserving surgery for breast cancer and carcinoma in situ: A single-centre study of 1575 consecutive cases. Breast. 2014; 23(6): 784–9. doi:10.1016/j.breast.2014.08.011.; Tiezzi D.G., Andrade J.M., Marana H.R., Zola F.E., Peria F.M. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008 Aug; 34(8): 863–7. doi:10.1016/j.ejso.2008.01.015.; Amabile M.I., Mazouni C., Guimond C., Sarfati B., Leymarie N., Cloutier A.S., Bentivegna E., Garbay J.R., Kolb F., Rimareix F. Factors Predictive of Re-excision After Oncoplastic Breast-conserving Surgery. Anticancer Res. 2015 Jul; 35(7): 4229–34.; Volders J.H., Haloua M.H., Krekel N.M., Negenborn V.L., Barbé E., Sietses C., Jóźwiak K., Meijer S., van den Tol M.P. Neoadjuvant chemotherapy in breast-conserving surgery Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol. 2016 Jul; 42(7): 986–93. doi:10.1016/j.ejso.2016.02.252.; Sadetzki S., Oberman B., Zipple D., Kaufman B., Rizel S., Novikov I., Papa M.Z. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol. 2005 Jun; 12(6): 480–7. doi:10.1245/ASO.2005.07.021.; Fukutomi T. Clinical practice and outcome of breast-conserving treatment: the effectiveness of preoperative systemic chemotherapy. Breast Cancer. 2006; 13(2): 147–51. doi:10.2325/jbcs.13.147.; Straver M.E., Rutgers E.J., Rodenhuis S., Linn S.C., Loo C.E., Wesseling J., Russell N.S., Oldenburg H.S., Antonini N., Vrancken Peeters M.T. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010; 17(9): 2411–8. doi:10.1245/s10434-010-1008-1.; van Riet Y.E., Maaskant A.J., Creemers G.J., van Warmerdam L.J., Jansen F.H., van de Velde C.J., Rutten H.J., Nieuwenhuijzen G.A. Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed. Eur J Surg Oncol. 2010 Feb; 36(2): 164–9. doi:10.1016/j.ejso.2009.10.009.; Gobardhan P.D., de Wall L.L., van der Laan L., ten Tije A.J., van der Meer D.C., Tetteroo E., Poortmans P.M., Luiten E.J. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013; 24(3): 668–73. doi:10.1093/annonc/mds475.; Mazouni C., Naveau A., Kane A., Dunant A., Garbay J.R., Leymarie N., Sarfati B., Delaloge S., Rimareix F. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. Breast. 2013 Dec; 22(6): 1189–93. doi:10.1016/j.breast.2013.07.055.; Donker M., Drukker C.A., Valdés Olmos R.A., Rutgers E.J., Loo C.E., Sonke G.S., Wesseling J., Alderliesten T., Vrancken Peeters M.J. Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. Ann Surg Oncol. 2013; 20(8): 2569–75. doi:10.1245/s10434-013-2921-x.; Gerber B., von Minckwitz G., Eidtmann H., Rezai M., Fasching P., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Solbach C., Jackisch C., Kunz G., Blohmer J.U., Huober J., Hauschild M., Nekljudova V., Loibl S., Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol. 2014 Aug; 21(8): 2517–24. doi:10.1245/s10434-014-3606-9.; Ramos M., Díez J.C., Ramos T., Ruano R., Sancho M., GonzálezOrús J.M. Intraoperative ultrasound in conservative surgery for nonpalpable breast cancer after neoadjuvant chemotherapy. Int J Surg. 2014; 12(6): 572–7. doi:10.1016/j.ijsu.2014.04.003.; Truin W., Vugts G., Roumen R.M., Maaskant-Braat A.J., Nieuwenhuijzen G.A., van der Heiden-van der Loo M., Tjan- Heijnen V.C., Voogd A.C. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer. Ann Surg Oncol. 2016 Jan; 23(1): 51–7. doi:10.1245/s10434-015-4603-3.; Rubio I.T., Esgueva-Colmenarejo A., Espinosa-Bravo M., Salazar J.P., Miranda I., Peg V. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment. Ann Surg Oncol. 2016 Jan; 23(1): 38–43. doi:10.1245/s10434-015-4935-z.; Chauhan A., Sharma M.M., Kumar K. Evaluation of Surgical Outcomes of Oncoplasty Breast Surgery in Locally Advanced Breast Cancer and Comparison with Conventional Breast Conservation Surgery. Indian J Surg Oncol. 2016 Dec; 7(4): 413–419. doi:10.1007/s13193-016-0549-6.; Peintinger F., Symmans W.F., Gonzalez-Angulo A.M., Boughey J.C., Buzdar A.U., Yu T.K., Hunt K.K., Singletary S.E., Babiera G.V., Lucci A., Meric-Bernstam F., Kuerer H.M. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6): 1248–54. doi:10.1002/cncr.22111.; Espinosa-Bravo M., Sao Avilés A., Esgueva A., Córdoba O., Rodriguez J., Cortadellas T., Mendoza C., Salvador R., Xercavins J., Rubio I.T. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011 Dec; 37(12): 1038–43. doi:10.1016/j.ejso.2011.08.136.; Carrara G.F., Scapulatempo-Neto C., Abrahão-Machado L.F., Brentani M.M., Nunes J.S., Folgueira M.A., Vieira R.A. Breast- conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up. Clinics (Sao Paulo). 2017; 72(3): 134–42. doi:10.6061/clinics/2017(03)02.; Choi J., Laws A., Hu J., Barry W., Golshan M., King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol. 2018 Nov; 25(12): 3541–3547. doi:10.1245/s10434-018-6702-4.; Li X., Dai D., Chen B., Tang H., Wei W. Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. World J Surg Oncol. 2017 Nov 28; 15(1): 210. doi:10.1186/s12957-017-1273-6.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan; 19(1): 27–39. doi:10.1016/S1470-2045(17)30777-5.; Зикиряходжаев А.Д., Волченко Н.Н., Рассказова Е.А., Ермощенкова М.В., Сухотько А.С., Фетисова Е.Ю. Оценка краев резекции при органосохраняющих операциях при раке молочной железы. Онкология. Журнал им. П.А. Герцена. 2015; 4(5): 4–7.; Volders J.H., Negenborn V.L., Spronk P.E., Krekel N.M.A., Schoonmade L.J., Meijer S., Rubio I.T., van den Tol M.P. Breast-conserving surgery following neoadjuvant therapy a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018 Feb; 168(1): 1–12. doi:10.1007/s10549-017-4598-5.; https://www.siboncoj.ru/jour/article/view/1764
-
3Academic Journal
Source: Вестник Казахского Национального медицинского университета.
Subject Terms: рак желудка, неоадъювантная лекарственная терапия, лечебный патоморфоз, регрессия опухоли, 3. Good health
File Description: text/html
